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Do They Show Us the Way?*Javier Sanz, MDTrue navigation begins in the human heart.
It’s the most important map of all.
—Elizabeth Kapu’uwailani Lindsey (1)SEE PAGE 40C ardiac magnetic resonance (CMR) is increas-ingly used in the diagnostic and prognosticworkup of cardiomyopathy. Beyond accu-
rately quantifying biventricular size and systolic
function, the main current strength of CMR is the
characterization of myocardial tissue. The technique
of late gadolinium enhancement (LGE), or transient
accumulation of paramagnetic extracellular contrast
agent in areas of myocardial scar and/or necrosis,
was developed more than 2 decades ago primarily
for the visualization of ischemic infarct. In the
chronic setting, LGE occurs because of localized
increased interstitial space (and therefore contrast
volume of distribution) within the scar (2). It has
been long known that it is also possible to use this
technique to depict scar in a variety of nonischemic
cardiomyopathies. In the speciﬁc setting of nonische-
mic dilated cardiomyopathy (NIDCM), LGE can assist
in determining the underlying etiology, and its pres-
ence and extent have been associated with increased
risk of death, malignant arrhythmia, and heart failure
events (3).
Strengths of LGE include excellent spatial resolu-
tion, which enables the visualization of very small
scars, and high contrast to noise ratio that makes
differentiation of ﬁbrotic and normal myocardium
simple; however, the technique relies on the presence
of normal (or seemingly normal) myocardial tissue.
When ﬁbrosis is diffuse, such as in cases of reactive as*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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weakness to detect an enlarged extracellular
compartment (2). In the last few years, alternative
approaches that rely on the quantiﬁcation of tissue
magnetic properties, speciﬁcally T1 times, have been
developed in an attempt to overcome this limitation.
Myocardial T1 mapping can be performed before or
after contrast administration, and histology valida-
tion studies have demonstrated correlations of T1
times with the extent of interstitial ﬁbrosis (4,5).
Whereas an increasing body of evidence indicates
that T1 mapping can detect subclinical myocardial
abnormalities in multiple clinical scenarios, data on
the potential prognostic implications of these ﬁnd-
ings are scant (6,7).In this issue of iJACC, Puntmann et al. (8)
explored the use of T1 mapping to predict outcome
speciﬁcally in NIDCM. At 4 centers, the investigators
prospectively enrolled 713 patients with a clinical
and echocardiographic diagnosis of NIDCM and no
evidence of coronary disease, signiﬁcant valvular
disease, inﬁltrative or deposit disorders, inﬂamma-
tion, or other primary cardiomyopathies. Using a
highly standardized modiﬁed look locker imaging
sequence on 1.5- or 3-T magnets, they performed
myocardial T1 mapping before and 15 min after the
administration of 0.1 to 0.2 mmol/kg of a single
contrast agent. Measured indexes included native
(pre-contrast) T1 times, post-contrast T1 times, and
extracellular volume (ECV), which combines blood
and myocardial pre- and post-contrast T1 times as
well as hematocrit. After exclusion of 53 patients lost
to follow-up and 23 with nondiagnostic studies, a
total of 637 patients were included and monitored
for the development of all-cause death (primary
endpoint) or a combination of heart failure death
or hospitalization (composite secondary endpoint).
During a median follow-up of 22 months, there were
28 deaths and 68 secondary endpoint events. In
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52univariate analyses, all T1 mapping indexes
(increased native T1 times and ECV and reduced
post-contrast T1 times) were associated with events,
with the exception of post-contrast T1 time and
mortality. Based on statistical criteria, the in-
vestigators selected native T1 mapping for subse-
quent multivariate analyses that considered clinical
characteristics, biventricular ejection fraction, left
ventricular volume and mass, and LGE presence and
extent. Native T1, together with LGE extent, was
independently associated with mortality (hazard ra-
tio per 10-ms change: 1.1; 95% CI: 1.05 to 1.13). Native
T1, together with right ventricular ejection fraction,
also predicted heart failure events (hazard ratio: 1.1;
95% CI: 1.04 to 1.11).
Puntmann et al. (8) are to be congratulated for
providing important new evidence on the prognostic
signiﬁcance of diffuse myocardial abnormalities in
NIDCM, as well as the potential of T1 mapping for
improving our understanding of cardiomyopathy.
Although an association of T1 maps with impaired
outcomes had been reported in all-comers to CMR
(6,7), this is the ﬁrst large, multicenter study to spe-
ciﬁcally test this question in NIDCM. The evaluation
of myocardial abnormalities using different T1 map
indexes is another strength of the paper. Although
current consensus documents recommend ECV as the
preferred approach (4), potential clinical superiority
of one method versus another will need to be deter-
mined from clinical studies such as this. Although
ECV methodology has been optimized for the quan-
tiﬁcation of predominantly interstitial expansion,
native T1 times likely reﬂect a combination of changes
in vascular, interstitial, and cellular compartments
and may provide different or complementary infor-
mation. Conversely, although the investigators
selected native T1 mapping for ultimate testing in
their multivariate models, this should not be inter-
preted as proof of superiority either. It is important to
note that only 1 method was selected to avoid
collinearity and that it only marginally outperformed
the others. Post-contrast T1 mapping is inherently
more sensitive to inaccuracies, which may have been
exaggerated by the use of varying contrast doses inthis study. Similarly, hematocrit values for ECV
quantiﬁcation were missing in a substantial propor-
tion of patients and were not collected at the time of
CMR, limitations that may have had some impact on
the accuracy of the technique and the observed
ﬁndings.
A few other aspects of the study deserve consid-
eration. Given the small number of events, adjust-
ments were made for only a limited number of
confounders. Although T1 maps remained in the
models after powerful markers of outcome such as
ejection fraction or LGE were considered, full
adjustment unfortunately could not be performed,
and the prognostic value of T1 maps in NIDCM will
require conﬁrmation in larger series. Explicitly, given
that many prior studies in NIDCM tested the prog-
nostic signiﬁcance of septal LGE, the complementary
value of T1 mapping over this speciﬁc LGE pattern
needs to be further evaluated. It would also be
interesting to explore if these subclinical indexes of
myocardial disease are additive to other prognostic
markers of subclinical disease, such as myocardial
deformation (9). Of note, none of the patients un-
derwent transplant or ventricular assist device im-
plantation, suggesting that this cohort was not
representative of the sickest patients with NIDCM and
that the ﬁndings should not be extrapolated to end-
stage disease.
Undoubtedly, many uncertainties remain. T1
maps are starting to show us new ways for the
evaluation of myocardial disease; we will need to
better understand what they are telling us and
whether they point us in the right directions. The
outcomes study by Puntmann et al. is an important
step forward and provides reassurance that these
maps are not misleading us. The journey has just
started and there is long road ahead, but it prom-
ises to be worthy!
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